Form 4: WBA Director Janice Babiak Receives Phantom Stock Grant

Walgreens Boots Alliance director Janice M. Babiak received an annual phantom stock grant of 16,820.86 units as compensation.

Summary

• Janice M. Babiak, a Director of Walgreens Boots Alliance, Inc. (WBA), received an annual phantom stock grant.
• The grant, dated August 13, 2025, consists of 16,820.86 phantom stock units.
• Each phantom stock unit is the economic equivalent of one share of WBA common stock.
• The grant was issued as non-employee director compensation under the Amended and Restated 2021 Omnibus Incentive Plan.
• These units are granted in arrears for services rendered over the prior year.
• The phantom stock units will be settled following the termination of service as a director.
• Following this transaction, Janice M. Babiak beneficially owns a total of 99,494.27 phantom stock units.
• The total beneficial ownership includes phantom stock units issued in lieu of dividends on previously outstanding units.
• The price of the derivative security was $11.89 per unit.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. This is a routine compensation filing, indicating standard corporate governance practices. It's not a major event but reflects ongoing operations.

Positives

• The grant of phantom stock units aligns the director's interests with shareholder value, as the units are equivalent to common stock.
• The compensation structure, tied to the 2021 Omnibus Incentive Plan, indicates a structured approach to director remuneration.

Future Outlook

The phantom stock units are to be settled following the termination of service as a director, indicating a long-term retention mechanism.

Industry Context

This is a standard compensation practice for non-employee directors in publicly traded companies, particularly within the retail pharmacy and healthcare industry, aiming to align director interests with long-term company performance.

Comparison to Industry Standards

• Granting phantom stock or restricted stock units (RSUs) as part of non-employee director compensation is a common practice across various industries, including retail and healthcare, for companies like CVS Health (CVS) or Rite Aid (RAD).
• The practice aims to align director incentives with shareholder value, similar to how directors at companies such as Walmart (WMT) or Target (TGT) might receive equity-based compensation.
• The specific amount and valuation ($11.89 per unit) would need comparison to WBA's peer group's director compensation disclosures (e.g., in proxy statements) to assess if it's within typical ranges, but the mechanism itself is standard.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns director interests with shareholder value, as the phantom stock units are tied to the company's common stock performance.

Next Steps

• Settlement of phantom stock units will occur following the termination of Janice M. Babiak's service as a director.

Key Dates

Recommendation

This Form 4 filing details a routine phantom stock grant to a non-employee director as part of their compensation. It reflects standard corporate governance practices aimed at aligning director incentives with shareholder interests. The filing does not contain any new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, an investor would likely maintain their current position based solely on this filing.

Keywords

Walgreens Boots Alliance, WBA, SEC Form 4, Phantom Stock, Director Compensation, Executive Compensation, Insider Trading, Equity Grant, Corporate Governance